Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV Infections

In brief

HIV is characterized by frequent immune system activation. Early in the course of infection the body establishes an immune activation "set point" related to the amount of HIV in the blood stream. This set point affects the rate of CD4 cell loss. Without CD4 cells, or with very low levels of CD4 cells, the body cannot fight off illness. This is known as immunodeficiency. If left untreated HIV can lead to extreme immunodeficiency and AIDS. Evidence suggests that by decreasing the rate of immune system activation, immune deficiency progression could be prevented. The purpose of this study is to learn how well chloroquine can reduce the level of immune activation and to test the safety and tolerance of chloroquine in people infected with HIV.

Key facts

Study ID: NCT00819390
Run by: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
People needed: 70
Starts: 2009-03-01
Expected to finish: 2013-05-01
Last updated by the study team: 2014-10-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

HIV-1 infected
Certain specified laboratory values obtained within 30 days prior to study entry. More information on this criterion can be found in the study protocol.
Documentation that pre-entry specimen for the primary immune activation endpoint responses has been obtained
Female participants of reproductive potential must have a negative pregnancy test performed within 24 hours prior to study entry
If engaging in sexual activity, female participants must use adequate forms of contraception while receiving study treatment and for 4 weeks after stopping the treatment. More information on this criterion can be found in the study protocol.
Ability and willingness to provide informed consent
Additional Inclusion Criteria for Off-ART Participants:
No antiretroviral therapy (ART) for at least 6 months prior to study entry and not likely to start within the 6 months after study entry
CD4 cell count greater than or equal to 400 cells/mm3 at screening, obtained within 30 days prior to study entry
For participants with previous ART use, documentation or recall of nadir CD4 cell count greater than or equal to 200 cells/mm3
HIV-1 RNA viral load greater than or equal to 1,000 copies/mL obtained within 30 days prior to study entry
No history of CDC category C AIDS-related opportunistic infections
Karnofsky performance score greater than or equal to 70 within 30 days prior to study entry
Additional Inclusion Criteria for On-ART Participants:
Receiving ART, defined as a regimen that includes three or more antiretroviral medications, for at least 24 months prior to study entry
Required documentation that all HIV-1 viral loads (at least two) were below 400 copies/mL. More information on this criterion can be found in the study protocol.
Screening HIV-1 RNA <200 copies/mL within 30 days prior to study entry. More information on this criterion can be found in the study protocol.
CD4 cell count <350 cells/mm3 at screening, obtained within 30 days prior to study entry

You may not qualify if…

Continuous use of certain specified medication for more than 3 days within 30 days prior to study entry. More information on this criterion can be found in the study protocol.
Use of chloroquine or hydroxychloroquine within 3 months prior to study entry
Known history of hypersensitivity to 4-aminoquinoline compounds (such as chloroquine or hydroxychloroquine)
Active drug or alcohol use or dependence that, in the opinion of the investigator would interfere with adherence to study requirements
Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry
Renal insufficiency, defined as serum creatinine greater than 1.5 mg/dL, within 30 days prior to study entry
History of retinal disease (i.e. confirmed retinopathy by ophthalmologic examination)
History of neoplasm, within 5 years prior to study entry, other than treated in situ carcinoma or basal-cell or localized squamous cell carcinoma of the skin
Glucose-6-phosphate dehydrogenase (G6PD) deficiency at screening
History of porphyria
History of psoriasis
History of cirrhosis
History of seizure disorder
History of tinnitus (ear and/or head noise lasting more than 5 minutes that occurs more often than once per week) or history of sudden hearing loss
History of myopathy
History of cardiac conduction abnormality or cardiomyopathy. More information on this criterion can be found in the study protocol.
Additional Exclusion Criteria for On-ART Participants:
Plans to change ART regimen with the 6 months after study entry (change in ART regimen is only permitted if due to toxicity)

Where it is running

Washington University CRS (2101) — St Louis, Missouri, United States
Cornell CRS (7804) — New York, New York, United States
Unc Aids Crs (3201) — Chapel Hill, North Carolina, United States
Univ. of Cincinnati CRS (2401) — Cincinnati, Ohio, United States
Case CRS (2501) — Cleveland, Ohio, United States
MetroHealth CRS (2503) — Cleveland, Ohio, United States
Hosp. of the Univ. of Pennsylvania CRS (6201) — Philadelphia, Pennsylvania, United States
Pittsburgh CRS (1001) — Pittsburgh, Pennsylvania, United States
Vanderbilt Therapeutics CRS (3652) — Nashville, Tennessee, United States
Alabama Therapeutics CRS (5801) — Birmingham, Alabama, United States
Ucsd, Avrc Crs (701) — San Diego, California, United States
University of Colorado Hospital CRS (6101) — Aurora, Colorado, United States
Georgetown University CRS (GU CRS) (1008) — Washington D.C., District of Columbia, United States
Johns Hopkins Adult AIDS CRS (201) — Baltimore, Maryland, United States
Massachusetts General Hospital ACTG CRS (101) — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.